Emerging PARP inhibitors for treating breast cancer

Abstract : Some breast cancers harbor defects in DNA repair pathways, including BRCA1 and BRCA2 mutations, leading to a genomic instability. Compromised DNA-damage repair response is found in 11 to 42% of triple negative breast cancers, with a frequency varying according to family history and ethnicity. The oral PARP inhibitors are a promising strategy in breast cancer exploiting Homologous Deficient Recombination deficiency (HRD) by a synthetic lethal approach. Several PARP inhibitors have currently reached early phase trials with studies on going in the adjuvant, neoadjuvant and metastatic setting. Area covered: Here, we review completed and ongoing trials with PARP inhibitors as well as their mechanisms of activity and acquired resistance. Expert opinion: PARP inhibitors show promising results in breast cancer. However, several issues are raised including the identification of biomarkers to predict treatment response and strategies to counteract emerging resistance.
Document type :
Journal articles
Complete list of metadatas

https://www.hal.inserm.fr/inserm-01977751
Contributor : Elizabeth Bernardo <>
Submitted on : Friday, January 11, 2019 - 9:08:58 AM
Last modification on : Monday, May 20, 2019 - 3:32:02 PM

Identifiers

Citation

Marie Robert, Anne Patsouris, Jean-Sébastien Frenel, Carole Gourmelon, Paule Augereau, et al.. Emerging PARP inhibitors for treating breast cancer. Expert Opinion on Emerging Drugs, Informa Healthcare, 2018, 23 (3), pp.211-221. ⟨10.1080/14728214.2018.1527900⟩. ⟨inserm-01977751⟩

Share

Metrics

Record views

54